InvaGen Recalls Testosterone Cypionate Injection Due to Particulate Matter
InvaGen Pharmaceuticals is recalling specific lots of Testosterone Cypionate Injection because of the presence of particulate matter. The affected vials were distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates temporary or medically reversible adverse health consequences. The hazard is particulate matter, which is a quality defect rather than a high-risk pathogen or structural defect, fitting the Moderate severity criteria for minor labeling or low-risk contamination issues.
Plain-English summary
InvaGen Pharmaceuticals, Inc. is recalling specific lots of Testosterone Cypionate Injection, USP, 200 mg/mL, 1 mL Vial, Single Dose. The recall was initiated due to the presence of particulate matter in the product. The affected product is manufactured by Cipla Ltd. in India for Cipla USA, Inc.
The recall covers 692,538 vials distributed nationwide in the U.S.A. The specific lot numbers and expiration dates are listed in the recall documentation, including lots expiring in December 2019, April 2020, May 2020, June 2020, July 2020, August 2020, and October 2020.
Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or pharmacist for guidance. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- TESTOSTERONE CYPIONATE (TESTOSTERONE CYPIONATE)
- Brand
- TESTOSTERONE CYPIONATE
- Manufacturer
- InvaGen Pharmaceuticals, Inc.
- Category
- Drug — Injection
- Hazard
- Affected units
- 692,538
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #:GH80009
- GH80010
- GH80011 Exp 12/2019
- GH80568
- GH80575
- GH80579
- GH80580
- GH80581
- GH80582 Exp 4/2020
- GH80646
- GH80664
- GH80665
- GH80684
- GH80699
- GH80700
- GH80701
- GH80746
- GH80761
- GH80765
- GH80777 Exp 05/2020
UPCs (3)
- 0369097536374
- 0369097537371
- 0369097537319
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by InvaGen Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · TESTOSTERONE CYPIONATE
- ModerateTestosterone Cypionate Injection Recalled for Insoluble Crystals
FDA (Drugs) · 2025-04-23
- HighTestosterone Cypionate Injection Recalled for Manufacturing Defect
FDA (Drugs) · 2023-04-12
- HighTestosterone Cypionate Injection Recalled for Water Leakage in Manufacturing
FDA (Drugs) · 2022-07-20
- ModerateTestosterone Cypionate Injectable Drug Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-07-13
- HighTestosterone Cypionate Injectable Recalled for Manufacturing Quality Issues
FDA (Drugs) · 2022-06-29
Same manufacturer · InvaGen Pharmaceuticals, Inc.
See all →- SeverePrescription Vigabatrin Powder Recalled for Defective Container Leakage Risk
FDA (Drugs) · 2024-01-17
- LowInvaGen Recalls Gabapentin Tablets Due to Impurity Test Failure
FDA (Drugs) · 2020-05-27
- ModerateInvaGen Recalls Testosterone Topical Solution Due to Defective Container
FDA (Drugs) · 2019-07-10
- ModerateInvaGen Recalls Testosterone Cypionate Injection Due to Particulate Matter
FDA (Drugs) · 2019-04-24
- HighInvaGen Recalls Testosterone Cypionate Injection Due to Particulate Matter
FDA (Drugs) · 2019-04-24
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26